XEOMIN® (botulinum toxin type A) individualised body weight-adapted dosing scheme[1]

For the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological/ neurodevelopmental disorders.[1]

XEOMIN® **total dose** ranges from **20 to 75 units** depending on the **individual body weight.** The dose is distributed by a **3:2 ratio** to the **parotid and the submandibular glands.**[1]

Body weight (kg)	Parotid gland, each side		Submandibular gland, each side		Total dose (both glands, both sides)
	Dose per gland (Units)	Volume per injection (ml)	Dose per gland (Units)	Volume per injection (ml)	
≥ 12 to < 15	6	0.24	4	0.16	20 units
≥ 15 to < 19	9	0.36	6	0.24	30 units
≥ 19 to < 23	12	0.48	8	0.32	40 units
≥ 23 to < 27	15	0.60	10	0.40	50 units
≥ 27 to < 30	18	0.72	12	0.48	60 units
≥ 30	22.5	0.90	15	0.60	75 units

XEOMIN® is injected directly into the salivary glands providing **targeted treatment for paediatric chronic sialorrhea.**[1]

Local anaesthesia, sedation, or anaesthesia in combination with sedation may be offered prior to injection after a careful benefit-risk evaluation and per local site practice.[1] In the SIPEXI study, a total of 162 (64%) subjects received local anaesthetic, 59 (23%) had a general anaesthetic and hypnotics/sedatives were received by 63 (25%) of subjects.[2]

ATC Class Level 3	Placebo group (6-17 years) (N=72) n (%)	Xeomin group (6-17 years) (N=148) n (%)	Xeomin group (2-5 years) (N=35) n (%)
Local Anaesthetic	42 (58.3)	95 (64.2)	25 (71.4)
General Anaesthetic	17 (23.6)	38 (25.7)	4 (11.4)
Hypnotics and sedatives	16 (22.2)	41 (27.7)	6 (17.1)

XEOMIN® has a **treatment effect of at least 16 weeks**. Patients may receive **up to 3 injections a year.**[1,3]

1. XEOMIN® Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/6202
2. Data on file, REF-1362. Merz Pharmaceuticals. September 2021
3. Berweck S, et al. Neurology.2021;97(14):e1425-e1436.

Merz Therapeutics is a business of Merz Pharmaceuticals GmbH
Prescribing information can be found on the reverse.

Click here for prescribing information

MERZ THERAPEUTICS

XEOMIN® Botulinum neurotoxin type A

Helping patients achieve their goals

M-XEO-UKI-1157 Date of preparation: January 2022